Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

Sector Expert: Kevin Little

3D Signatures Inc.

Image: Kevin Little

Dr. Kevin Little is the chief scientific officer of 3D Signatures, overseeing the design, development and implementation of the company's research and clinical programs. Prior to his position at 3DS, Little worked as an independent consultant, offering strategic advisory services to help facilitate new life sciences collaborations for public and private sector clients, including Thomson Reuters, Illumina, Janssen, McGill University and the Global Alliance for Genomics and Health. Little previously led the PERFORM Centre, a $36 million health research and community services complex, as the Founding Chief Administrative Officer. Before returning to Canada to lead the start-up of the PERFORM Centre, Little spent several years leading the New Zealand government's economic development efforts to build strategic investment relationships across the biotechnology industry sector. Little holds a Bachelor of Science degree in Biology from the University of Victoria, and earned his Ph.D. in Experimental Medicine from McGill University, specializing in DNA repair and functional human genomics.

Recent Interviews

3D Signatures' Platform Taps into the Power of the Genome (5/10/17)

How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment.

Due to permission requirements, not all quotes are shown.